SG11202113312VA - Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist - Google Patents
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonistInfo
- Publication number
- SG11202113312VA SG11202113312VA SG11202113312VA SG11202113312VA SG11202113312VA SG 11202113312V A SG11202113312V A SG 11202113312VA SG 11202113312V A SG11202113312V A SG 11202113312VA SG 11202113312V A SG11202113312V A SG 11202113312VA SG 11202113312V A SG11202113312V A SG 11202113312VA
- Authority
- SG
- Singapore
- Prior art keywords
- antagonist
- administering
- methods
- specific immunotherapy
- treating allergy
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title 1
- 239000013566 allergen Substances 0.000 title 1
- 208000026935 allergic disease Diseases 0.000 title 1
- 230000007815 allergy Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962882992P | 2019-08-05 | 2019-08-05 | |
EP20315351 | 2020-07-16 | ||
PCT/US2020/044958 WO2021026203A1 (en) | 2019-08-05 | 2020-08-05 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202113312VA true SG11202113312VA (en) | 2021-12-30 |
Family
ID=72088424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202113312VA SG11202113312VA (en) | 2019-08-05 | 2020-08-05 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
Country Status (12)
Country | Link |
---|---|
US (2) | US11504426B2 (en) |
EP (1) | EP4010001A1 (en) |
JP (1) | JP2022543815A (en) |
KR (1) | KR20220042217A (en) |
CN (1) | CN114173819A (en) |
AU (1) | AU2020325021B2 (en) |
BR (1) | BR112022000581A2 (en) |
CA (1) | CA3147068A1 (en) |
IL (1) | IL289613B2 (en) |
MX (1) | MX2022001030A (en) |
SG (1) | SG11202113312VA (en) |
WO (1) | WO2021026203A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI755763B (en) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
TWI634900B (en) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
RU2704999C2 (en) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Method of treating skin infection by administering antagonist il-4r |
MX2019002344A (en) | 2016-09-01 | 2019-09-06 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist. |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
CA3099066A1 (en) | 2018-05-13 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
US11964016B2 (en) | 2019-03-21 | 2024-04-23 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
BR9205967A (en) | 1991-05-03 | 1994-07-26 | Seragen Inc | Interleukin receptor-labeled molecules treatment of inflammatory arthritis |
JP3315427B2 (en) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | Dermatitis treatment |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
ZA946875B (en) | 1993-09-07 | 1995-07-06 | Smithkline Beecham Corp | Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
ES2259478T3 (en) | 1998-09-18 | 2006-10-01 | Dynavax Technologies Corporation | METHODS TO TREAT DISORDERS ASSOCIATED WITH IGE AND COMPOSITIONS FOR THIS USE. |
DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
CN100496579C (en) | 2000-07-26 | 2009-06-10 | 株式会社凤凰堂 | Antipruritic compositions and compositions for wound healing |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
JP2004529180A (en) | 2001-05-11 | 2004-09-24 | ノバルティス アクチエンゲゼルシャフト | Compositions for use in treating IgE-related disorders |
CA2447795A1 (en) | 2001-05-23 | 2002-11-28 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
EP2298717B1 (en) | 2001-11-30 | 2015-10-28 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
MXPA04009418A (en) | 2002-03-29 | 2005-06-08 | Schering Corp | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same. |
WO2004047793A1 (en) | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Pharmaceutical allergen product |
WO2004070010A2 (en) | 2003-02-01 | 2004-08-19 | Tanox, Inc. | A method for generating high affinity antibodies |
US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
CA2543982C (en) | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
CA2550933A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
US7410781B2 (en) | 2004-02-27 | 2008-08-12 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 specific polypeptides and therapeutic uses thereof |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP5234445B2 (en) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | Drug |
US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
JP4221018B2 (en) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | Head protection airbag device |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
ES2859825T3 (en) | 2006-10-02 | 2021-10-04 | Regeneron Pharma | Human antibodies with high affinity for the human IL-4 receptor |
UA102994C2 (en) | 2007-03-22 | 2013-09-10 | Дженентек, Инк. | ANTIBODY THAT SPECIFICALLY BINDS TO IgE/M1' AND INDUCES APOPTOSIS IN IgE-EXPRESSING B-CELLS |
EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
US8637239B2 (en) | 2007-11-05 | 2014-01-28 | The Board Of Trustees Of The University Of Illinois | Minimally-invasive measurement of esophageal inflammation |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DE202008006598U1 (en) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergy vaccine formulation for mucosal administration |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
AU2009322556A1 (en) | 2008-12-01 | 2011-07-21 | Children's Hospital Medical Center | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis |
EP2414520A2 (en) | 2009-03-31 | 2012-02-08 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
ES2534558T3 (en) | 2009-09-07 | 2015-04-24 | Dbv Technologies | Eosinophilic esophagitis treatment method |
US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
EP2585075B8 (en) | 2010-06-24 | 2021-09-22 | ViroPharma Biologics LLC | Methods of treatment for esophageal inflammation |
EA028945B1 (en) | 2010-10-06 | 2018-01-31 | Ридженерон Фармасьютикалз, Инк. | STABLE LIQUID PHARMACEUTICAL FORMULATIONS CONTAINING ANTIBODIES TO HUMAN INTERLEUKIN-4 RECEPTOR ALPHA (hIL-4Rα) |
RU2453303C1 (en) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Pharmaceutical composition for atopic dermatitis |
US20130324435A1 (en) | 2011-01-06 | 2013-12-05 | Children's Hospital Medical Center | Esophageal cytokine expression profiles in eosinophilic esophagitis |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
EP2723899B1 (en) | 2011-06-21 | 2020-11-18 | Children's Hospital Medical Center | Diagnostic methods for eosinophilic esophagitis |
CN103974706A (en) | 2011-10-06 | 2014-08-06 | N·V·努特里奇亚 | Treatment of eosinophilic esophagitis |
EP2790696A1 (en) | 2011-12-16 | 2014-10-22 | Atopix Therapeutics Limited | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
JP2015506950A (en) | 2012-01-31 | 2015-03-05 | ジェネンテック, インコーポレイテッド | Anti-IG-EM1 'antibody and method using the same |
WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
HUE064945T2 (en) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
PL2892927T3 (en) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
WO2014059178A1 (en) | 2012-10-10 | 2014-04-17 | Rhode Island Hospital | Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis |
EP2953972B1 (en) | 2013-02-05 | 2020-07-08 | EngMab Sàrl | Method for the selection of antibodies against bcma |
TWI755763B (en) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
CN111437387A (en) | 2013-06-21 | 2020-07-24 | 赛诺菲生物技术公司 | Methods of treating nasal polyposis by administering I L-4R antagonists |
TWI634900B (en) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
RU2552929C1 (en) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases |
JP6673840B2 (en) | 2014-02-21 | 2020-03-25 | サノフィ・バイオテクノロジー | Methods for treating or preventing asthma by administering an IL-4R antagonist |
RU2704999C2 (en) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Method of treating skin infection by administering antagonist il-4r |
KR20230158131A (en) | 2014-11-14 | 2023-11-17 | 사노피 바이오테크놀로지 | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
JP2019505554A (en) | 2016-02-19 | 2019-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Method for enhancing the effectiveness of a vaccine by administering an IL-4R antagonist |
TWI728172B (en) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | Methods of treating eosinophilic esophagitis |
MX2019002344A (en) * | 2016-09-01 | 2019-09-06 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist. |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
IL310371A (en) | 2016-09-22 | 2024-03-01 | Regeneron Pharma | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
EP4269594A3 (en) | 2017-02-17 | 2023-12-20 | Fred Hutchinson Cancer Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
EP3703818B1 (en) | 2017-10-30 | 2023-11-01 | Sanofi Biotechnology | Il-4r antagonist for use in a method for treating or preventing asthma |
CA3099066A1 (en) | 2018-05-13 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
US11964016B2 (en) | 2019-03-21 | 2024-04-23 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
WO2021026205A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
BR112022011098A2 (en) | 2019-12-09 | 2022-09-20 | Sanofi Biotechnology | METHODS FOR TREATMENT OF DIGITALLY IDENTIFIED IL-4/IL-13-RELATED DISORDERS |
EP4153300A1 (en) | 2020-05-22 | 2023-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
-
2020
- 2020-08-05 IL IL289613A patent/IL289613B2/en unknown
- 2020-08-05 SG SG11202113312VA patent/SG11202113312VA/en unknown
- 2020-08-05 CA CA3147068A patent/CA3147068A1/en active Pending
- 2020-08-05 EP EP20757494.8A patent/EP4010001A1/en active Pending
- 2020-08-05 JP JP2022507353A patent/JP2022543815A/en active Pending
- 2020-08-05 CN CN202080055380.2A patent/CN114173819A/en active Pending
- 2020-08-05 KR KR1020227007521A patent/KR20220042217A/en active Search and Examination
- 2020-08-05 MX MX2022001030A patent/MX2022001030A/en unknown
- 2020-08-05 BR BR112022000581A patent/BR112022000581A2/en unknown
- 2020-08-05 US US16/985,665 patent/US11504426B2/en active Active
- 2020-08-05 WO PCT/US2020/044958 patent/WO2021026203A1/en unknown
- 2020-08-05 AU AU2020325021A patent/AU2020325021B2/en active Active
-
2022
- 2022-10-19 US US18/047,972 patent/US20230293682A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL289613A (en) | 2022-03-01 |
WO2021026203A1 (en) | 2021-02-11 |
JP2022543815A (en) | 2022-10-14 |
US20210038715A1 (en) | 2021-02-11 |
AU2020325021B2 (en) | 2024-05-30 |
US11504426B2 (en) | 2022-11-22 |
US20230293682A1 (en) | 2023-09-21 |
AU2020325021A1 (en) | 2022-01-06 |
CN114173819A (en) | 2022-03-11 |
KR20220042217A (en) | 2022-04-04 |
IL289613B1 (en) | 2023-05-01 |
BR112022000581A2 (en) | 2022-03-03 |
CA3147068A1 (en) | 2021-02-11 |
IL289613B2 (en) | 2023-09-01 |
MX2022001030A (en) | 2022-04-26 |
EP4010001A1 (en) | 2022-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202113312VA (en) | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist | |
IL273678A (en) | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor | |
IL274134A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
ZA202004919B (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
SG11202100972WA (en) | Block chain-based claim settlement method and apparatus | |
IL269593A (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
IL259847A (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
DK3310814T3 (en) | Humanized and affinity matured antibodies against FcRH5 and methods of use | |
PT3107575T (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
IL269074A (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
MX2016007208A (en) | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE. | |
IL304240A (en) | Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist | |
IL278812A (en) | Peptides and methods for detecting peanut allergies | |
HK1251582A1 (en) | Humanized anti-tau(ps422) antibodies and methods of use | |
IL281769A (en) | Cd40l antagonist and uses thereof | |
IL292198A (en) | Tim-3 inhibitors and uses thereof | |
IL292238A (en) | Clec12a antibody fragment sequences and methods | |
SG11201912786WA (en) | Block Chain-based File Protection Method and Terminal Device | |
IL294066A (en) | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist | |
IL289731A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
MX2015013380A (en) | Yeast-based immunotherapy for chordoma. | |
SG10202011023YA (en) | Dna monoclonal antibodies targeting il-6 and cd126 | |
SG11202004154SA (en) | Aptamer for adamts5 and use for aptamer for adamts5 | |
PT3703818T (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
IL284901A (en) | Methods of purifying an allergen extract |